Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

289
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
289
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

286
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
286
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

290
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
290
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

317
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
317
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

300
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
300
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

107
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
107

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of sarcopenia in patients with Takayasu arteritis: A cross-sectional observational study.

Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition·2026
Same author

Autonomic dysfunction in systemic lupus erythematosus and systemic sclerosis.

Lupus·2026
Same author

Editorial: Insights into the diagnosis, pathogenesis and management of Takayasu arteritis.

Frontiers in immunology·2026
Same author

Social appearance anxiety and its associations with anxiety, depressive symptoms, and health-related quality of life in systemic sclerosis: a cross-sectional study.

Clinical rheumatology·2026
Same author

Long-term remission and monocyclic course in Still's disease patients starting canakinumab early: data from the international AIDA network registry.

Seminars in arthritis and rheumatism·2026
Same author

Outcomes of Vascular Interventions in Takayasu Arteritis and the Role of Biologic Therapy: A Multicenter Retrospective Study.

International journal of rheumatic diseases·2026

Related Experiment Video

Updated: Nov 14, 2025

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.6K

Biologic treatments in Behçet's disease.

Fatma Alibaz-Öner1, Haner Direskeneli1

  • 1Division of Rheumatology, Department of Internal Medicine, Marmara University School of Medicine, İstanbul, Turkey.

European Journal of Rheumatology
|March 9, 2021
PubMed
Summary

Behçet's disease (BD) management is evolving. Biologic therapies targeting specific pathways show promise for severe cases, but more research is needed to confirm their long-term efficacy and safety.

Area of Science:

  • Rheumatology
  • Immunology
  • Ophthalmology

Background:

  • Behçet's disease (BD) poses significant health risks, particularly vascular and ocular complications.
  • Standard immunosuppressive treatments are insufficient for some patients, leading to disease relapses and damage.

Purpose of the Study:

  • To review the current understanding and emerging biologic treatments for Behçet's disease.
  • To evaluate the efficacy and safety of biologic agents in managing major organ involvement in BD.

Main Methods:

  • Literature review of studies on biologic treatments for Behçet's disease.
  • Analysis of data from large series and clinical observations of biologic agent use.

Main Results:

  • Tumor necrosis factor-α inhibitors and interferon-α are effective for refractory ocular, neurologic, vascular, and gastrointestinal involvement.

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.2K
Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis
06:39

Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis

Published on: October 27, 2023

1.2K

Related Experiment Videos

Last Updated: Nov 14, 2025

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.6K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.2K
Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis
06:39

Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis

Published on: October 27, 2023

1.2K
  • Anakinra, ustekinumab, IL-1 inhibitors, and tocilizumab show potential for mucocutaneous and ocular manifestations.

    • Conclusions:

    • Biologic therapies offer new avenues for treating severe Behçet's disease, especially major organ involvement.
    • Further randomized controlled trials are essential to establish the long-term efficacy, safety, and optimal use of biologics in BD.